← Leaderboards
James A Whitlock
Vanderbilt University
$419,106
Attributed
$419,106
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$419,106 · 4
By mechanism
U10$331,361 · 1
P30$87,745 · 2
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Scott Hiebert$33,340,607
- Julie A Sterling$3,669,071
- Michael Ian Miga$9,976,365
- Lynn M Matrisian$19,522,211
- David H Johnson$5,849,161
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsNeoplasm /Cancer ChemotherapyClinical ResearchOncologyBiomedical FacilityPediatric Neoplasm /CancerAntineoplasticsNeoplasm /CancerHealth Science Research SupportHuman SubjectHuman Therapy EvaluationClinical Trial Phase IDrug Administration Rate /DurationPharmacokineticsIntravenous AdministrationNeoplasm /Cancer Relapse /RecurrenceNeoplasm /Cancer PharmacologyNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer SurgeryNeuroblastomaOncology NursingStatistics /BiometryAcute Lymphocytic LeukemiaTissue Resource /Registry
Grant awards (17)
PROTOCOL REVIEW &MONITORING SYSTEM SCIENTIFIC REVIEW COMMITTEE$87,745
P30 · FY2004 · CA
CANCER IN CHILDREN$113,872
U10 · FY2002 · CA
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2002 · CA
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2002 · CA
CCG 09718 PEDIATRIC/INTRAVENOUS DOLASTATIN-10 IN REFRACTORY TUMORS$0
M01 · FY2002 · RR
CANCER IN CHILDREN$111,343
U10 · FY2001 · CA
CCG 09718 PEDIATRIC/INTRAVENOUS DOLASTATIN-10 IN REFRACTORY TUMORS$0
M01 · FY2001 · RR
CCG 09718 PEDIATRIC/INTRAVENOUS DOLASTATIN-10 IN REFRACTORY TUMORS$0
M01 · FY2001 · RR
CCG 09718 PEDIATRIC/INTRAVENOUS DOLASTATIN-10 IN REFRACTORY TUMORS$0
M01 · FY2001 · RR
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2001 · CA
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2001 · CA
CANCER IN CHILDREN$106,146
U10 · FY2000 · CA
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2000 · CA
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2000 · CA
CCG 09718 PEDIATRIC/INTRAVENOUS DOLASTATIN-10 IN REFRACTORY TUMORS$0
M01 · FY2000 · RR
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2000 · CA
Core--Clinical trial protocol review and monitoring system$0
P30 · FY2000 · CA